Employers, Benefit Plans and Opioids: Pain Management Alternatives
Free to International Foundation and ISCEBS members

Employers, Benefit Plans and Opioids: Pain Management Alternatives

Wednesday, August 31, 2022|3:00-4:30 p.m. ET

The opioid crisis is waging a war across the U.S. and Canada, with more than 600,000 people dying from opioid overdose. The Stanford-Lancet Commission reported in February 2022 that a staggering 1.2 million more are estimated to die due to overdose by 2029.

In this session, Cal Beyer and Dr. Brand Newland will provide strategies on how to protect your employees and their families from opioids through practical and proven first-exposure prevention strategies, including assessment methods to evaluate the risk in your organization and ways to prevent and mitigate exposure to first doses and/or addiction during medical and surgical procedures.

This webcast will help you:

• Identify the mental and physical effects of chronic pain, and learn about alternatives to opioids and opioid-sparing protocols

• Assess the human and financial consequences of opioids in the workplace, including absenteeism, presenteeism, and workers’ compensation and employee medical health benefit claims

• Learn how Enhanced Recovery After Surgery (ERAS) protocols optimize surgical outcomes in work- and/or home-related cases

• Discuss recommendations, resources and tools available to help companies and families address the risk of opioids, including practical first-exposure prevention strategies.

Brand A. Newland
Speaker: Brand A. Newland,  PharmD, MBA Chief Executive Officer,  Goldfinch Health Austin,  TX
Calvin Beyer
Speaker: Calvin Beyer,  CWP Vice President, Workforce Risk and Worker Wellbeing,  Holmes Murphy & Associates Minneapolis,  MN
Watch Now More Webcasts

In order to achieve a more secure and compliant experience, we no longer support Internet Explorer. Please use one of the browsers listed below:

  • Microsoft Edge
  • Google Chrome
  • Mozilla Firefox
  • Apple Safari

View our system requirements for more details.